Whole virus, inactivated, adjuvanted COVID-19 vaccine (Valneva)

N/A

Report date: 2022/04/25 15:47:25

Base Information

Drug NameWhole virus, inactivated, adjuvanted COVID-19 vaccine (Valneva)
Drug Alias NameVLA2001VLA-2001
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Inactivated vaccine > Whole microorganism inactivated vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2022/04/14
Country/TerritoryNetherlandsNew ZealandBahrain +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesValneva
China Registration ClassN/A

Develop Information

Active CompaniesValnevaValneva Austria GmbhIdt Biologika Gmbh
Inactive CompaniesNational Institute For Health Research, United KingdomCentro De Estudios En Infectogía PediatricaValneva SE
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A